At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 49 enrolled
Drug / intervention
Ruxolitinib Creamdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo
In Brief
A Phase 2 clinical trial evaluating Ruxolitinib Cream for Nonsegmental Vitiligo With Genital Involvement. Completed, enrolled 49 participants across 13 sites in 3 countries.
Detailed Summary
An open-label study in which participants with non-segmental vitiligo with genital involvement will apply ruxolitinib 1.5% cream twice a day (BID) to all depigmented areas (up to 10% BSA) for up to 48 weeks. Participants should continue to treat depigmented areas identified for treatment at baseline regardless of whether the area begins to improve or fully repigment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, France, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202420252026
First PostedMar 2023
Enrollment StartApr 2023
Primary CompletionMar 2025
TodayJul 2026
First PostedMar 2, 2023
Enrollment StartApr 11, 2023
Primary CompletionMar 6, 2025
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 3.3 years ago
Interventions
Ruxolitinib Creamdrug
Ruxolitinib cream will be applied twice daily for upto 48 weeks